Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Int J Radiat Oncol Biol Phys

Retrieve available abstracts of 256 articles:
HTML format



Single Articles


    July 2022
  1. SHEN X, Spratt DE, Dusetzina SB, Chen RC, et al
    Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures.
    Int J Radiat Oncol Biol Phys. 2022 Jul 30. pii: S0360-3016(22)02597.
    PubMed     Abstract available


  2. USMANI N, Ghosh S, Sanghera KP, Ong AD, et al
    Metformin for Prevention of Anthropometric & Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2022 Jul 27. pii: S0360-3016(22)00747.
    PubMed     Abstract available


  3. CHINNIAH S, Stish B, Costello BA, Pagliaro L, et al
    Radiotherapy in Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 22. pii: S0360-3016(22)00732.
    PubMed     Abstract available


  4. HAMMER L, Jiang R, Hearn J, Lashbrook J, et al
    A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 22. pii: S0360-3016(22)00736.
    PubMed     Abstract available


  5. CHOPADE P, Maitre P, David S, Panigrahi G, et al
    Common iliac node positive prostate cancer treated with curative radiotherapy: N1 or M1a?
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00731.
    PubMed     Abstract available


  6. BRAND DH, Tree AC
    Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
    Int J Radiat Oncol Biol Phys. 2022 Jul 14. pii: S0360-3016(22)00485.
    PubMed    


  7. HAO C, Ladbury C, Lyou Y, Manoukian S, et al
    Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation.
    Int J Radiat Oncol Biol Phys. 2022 Jul 5. pii: S0360-3016(22)00659.
    PubMed     Abstract available


  8. CHARGARI C, Haie-Meder C, Espenel S, Garcia MA, et al
    Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments.
    Int J Radiat Oncol Biol Phys. 2022;113:602-613.
    PubMed     Abstract available


    June 2022
  9. MURTHY V, Adsul K, Maitre P, Singhla A, et al
    Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study.
    Int J Radiat Oncol Biol Phys. 2022 Jun 17. pii: S0360-3016(22)00607.
    PubMed     Abstract available


  10. HALL WA, Karrison TG, Rosenthal SA, Amin MB, et al
    The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521.
    Int J Radiat Oncol Biol Phys. 2022 Jun 5. pii: S0360-3016(22)00555.
    PubMed     Abstract available


  11. RICH BJ, Montoya C, Jin WH, Spieler BO, et al
    Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00545.
    PubMed     Abstract available


  12. LUCIEN F, Kim Y, Qian J, Orme JJ, et al
    Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity.
    Int J Radiat Oncol Biol Phys. 2022 Jun 4. pii: S0360-3016(22)00544.
    PubMed     Abstract available


  13. ZAMBOGLOU C, Strouthos I, Sahlmann J, Farolfi A, et al
    Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy.
    Int J Radiat Oncol Biol Phys. 2022 Jun 2. pii: S0360-3016(22)00409.
    PubMed     Abstract available


  14. JIA AY, Spratt DE
    Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
    Int J Radiat Oncol Biol Phys. 2022;113:316-319.
    PubMed    


  15. ZELEFSKY MJ
    Are We Ready for Focal Dose Radio-Ablation in the Treatment of Localized Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2022;113:302-304.
    PubMed    


  16. MOHAMAD O, Feng F
    The Time to Evaluate the Impact of PET PSMAs on Management of Prostate Cancer Is Now.
    Int J Radiat Oncol Biol Phys. 2022;113:254-255.
    PubMed    


  17. BERGHEN C, De Meerleer G
    Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CT.
    Int J Radiat Oncol Biol Phys. 2022;113:252-253.
    PubMed    


  18. STENMAN J, Wickart-Johansson G, Sundquist F, Nilsson J, et al
    Five-Year Follow-up After Multimodal Treatment Incorporating HDR Brachytherapy for Bladder Prostate Rhabdomyosarcoma in Children.
    Int J Radiat Oncol Biol Phys. 2022;113:355-359.
    PubMed    


  19. TREE A, Griffin C, Syndikus I, Birtle A, et al
    Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2022;113:305-315.
    PubMed     Abstract available


    May 2022
  20. YANG F, Ghosh S, Yee D, Patel S, et al
    Patient-Reported Outcomes in a Prostate Cancer Hypofractionation Trial.
    Int J Radiat Oncol Biol Phys. 2022 May 7. pii: S0360-3016(22)00406.
    PubMed     Abstract available


  21. ZILLI T, Achard V, Guevelou JL
    Intraprostatic Urethra: The New Kid on the Block for Prostate Cancer Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2022;113:92-95.
    PubMed    


  22. DESS RT
    Personalized Medicine in Localized Prostate Cancer: Are We There Yet?
    Int J Radiat Oncol Biol Phys. 2022;113:77-79.
    PubMed    



  23. Erratum to: Sanders JW, Venkatesan AM, Levitt CA, et al. Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2021;109(2):614-625.
    Int J Radiat Oncol Biol Phys. 2022;113:238.
    PubMed    


  24. BECK M, Sassowsky M, Schar S, Mathier E, et al
    Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
    Int J Radiat Oncol Biol Phys. 2022;113:80-91.
    PubMed     Abstract available


  25. TWARD J, Lenz L, Flake DD II,, Rajamani S, et al
    The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
    Int J Radiat Oncol Biol Phys. 2022;113:66-76.
    PubMed     Abstract available


    April 2022
  26. ZAMBOGLOU DC, Spohn DSKB, Ruf PJ, Benndorf DM, et al
    PSMA-PET- and MRI-based focal dose escalated radiotherapy of primary prostate cancer: planned safety analysis of a non-randomized 2-armed phase II trial (ARO2020-01).
    Int J Radiat Oncol Biol Phys. 2022 Apr 22. pii: S0360-3016(22)00333.
    PubMed     Abstract available


  27. VIANI GA, Gouveia AG, Moraes FY, Cury FL, et al
    "Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI).
    Int J Radiat Oncol Biol Phys. 2022 Apr 15. pii: S0360-3016(22)00321.
    PubMed     Abstract available


  28. KWAN W, Bahl G, Kim D, Ye A, et al
    Acute Toxicity of Ultrahypofractionation Compared to Moderate Hypofractionation in Prostate Cancer Treatment - a Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2022 Apr 10. pii: S0360-3016(22)00319.
    PubMed     Abstract available


  29. DHERE VR, Schuster DM, Goyal S, Schreibmann E, et al
    Randomized Trial of Conventional- vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses.
    Int J Radiat Oncol Biol Phys. 2022 Apr 10. pii: S0360-3016(22)00318.
    PubMed     Abstract available


  30. THIRUTHANEESWARAN N, Turner SL
    Prostate Cancer Patients to Reap the Benefits of "Seeds" Planted by NRG Oncology/RTOG 0526.
    Int J Radiat Oncol Biol Phys. 2022;112:1123-1125.
    PubMed    


  31. CROOK J, Rodgers JP, Pisansky TM, Trabulsi EJ, et al
    Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
    Int J Radiat Oncol Biol Phys. 2022;112:1115-1122.
    PubMed     Abstract available


    March 2022
  32. ZUMSTEG ZS
    Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:744-746.
    PubMed    


    February 2022
  33. LAMPROU I, Kakouratos C, Tsolou A, Pavlidis P, et al
    Lipophagy-related protein perilipin-3 (PLIN3) and resistance of prostate cancer to radiotherapy.
    Int J Radiat Oncol Biol Phys. 2022 Feb 1. pii: S0360-3016(22)00079.
    PubMed     Abstract available


  34. TREE A
    Androgen Deprivation Therapy, Perseverance, and Greek Mythology.
    Int J Radiat Oncol Biol Phys. 2022;112:304-305.
    PubMed    


    January 2022
  35. RAMAN S, Keyes M, Oh J, Rousseau E, et al
    Patterns of prostate cancer recurrence after brachytherapy determined by PSMA PET/CT imaging.
    Int J Radiat Oncol Biol Phys. 2022 Jan 2. pii: S0360-3016(21)03437.
    PubMed     Abstract available


  36. GLICKSMAN RM, Berlin A
    FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:93-95.
    PubMed    


  37. HALL WA, Deshmukh S, Bruner DW, Michalski JM, et al
    Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2022;112:83-92.
    PubMed     Abstract available


  38. LEEMAN JE, Chen YH, Catalano P, Bredfeldt J, et al
    Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials.
    Int J Radiat Oncol Biol Phys. 2022;112:75-82.
    PubMed     Abstract available


    December 2021
  39. ROY S, Zaorsky NG, Bagshaw HP, Berlin A, et al
    An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Dec 16. pii: S0360-3016(21)03240.
    PubMed     Abstract available


  40. WILLETT GCECG, Chang DT, Czito BG, Liauw SL, et al
    Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors.
    Int J Radiat Oncol Biol Phys. 2021;111:1114-1117.
    PubMed    


  41. HARMON G, Chan D, Lee B, Miller C, et al
    Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiotherapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.
    Int J Radiat Oncol Biol Phys. 2021;111:1195-1203.
    PubMed     Abstract available


    November 2021
  42. ZAORSKY NG, Spratt DE
    Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?
    Int J Radiat Oncol Biol Phys. 2021;111:965-967.
    PubMed    


  43. ROY S, Spratt DE, Morgan SC, Zhou M, et al
    Association of Short-term Patient-reported Outcomes with Long-term Oncologic Outcomes in Localized Prostate Cancer Patients Treated with Radiotherapy and ADT in a Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 14. pii: S0360-3016(21)03118.
    PubMed     Abstract available


  44. HANNAN R, Salamekh S, Desai NB, Garant A, et al
    Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 10. pii: S0360-3016(21)03047.
    PubMed     Abstract available


  45. SINZABAKIRA F, Heemsbergen WD, Pos F, Incrocci L, et al
    Patient-reported outcomes in the acute phase of the randomized hypofractionated irradiation for prostate cancer (HYPRO) trial.
    Int J Radiat Oncol Biol Phys. 2021 Nov 2. pii: S0360-3016(21)03049.
    PubMed     Abstract available


  46. ENNIS RD, Vapiwala N
    The Fallacy of the Consultation and Informed Consent Process in Radiation Oncology Through the Lens of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111:643-646.
    PubMed    


  47. JASSAR H, Tai A, Chen X, Keiper T, et al
    Real-Time Motion Tracking Based on Orthogonal Cine MRI During MR-Guided Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  48. CHEN GP, Tai A, Omari EA, Bedi M, et al
    Real-Time Motion Tracking and Correction During Tomotherapy for Prostate Cancer: Impact of Fiducial Migration.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  49. BRENNEMAN RJ, Andruska N, Roy A, Waters MR, et al
    Characterization of a Novel Radiopaque Perirectal Hydrogel Spacer for Prostate Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  50. WU TC, Xiang M, Nickols NG, Tenn SE, et al
    Prostate-Centric vs. Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer With Simultaneous Integrated Boost: A Dosimetric Comparison.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  51. TAKAGI M, Hasegawa Y, Tateoka K, Takada Y, et al
    Dosimetric Study of Proton Therapy Using Scanning Method for Localized Prostate Cancer Patients in Comparison With Wobbler Method and Volumetric-Modulated Arc Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  52. GALLITTO M, Mayeda M, Hwang ME, Rayn K, et al
    Factors Contributing to Bladder Filling Variability in Patients Receiving Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  53. SONG Y, Ko WC, Tamas P, Hsu HY, et al
    Effects of Bladder Filling and Rectal Gas on Number of CBCT Scans and Treatment Time for Prostate Cancer Patients Undergoing EBRT.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  54. CARRASQUILLA M, O'Connor T, Zwart A, Danner M, et al
    Safety and Early Efficacy of Involved Field SBRT for Nodal Oligo-Recurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  55. POWELL A, Goldstein JP, Lucas ER, Long J, et al
    The Association Between Use of Hypofractionated Radiation Therapy for the Treatment of Prostate Cancer and Treatment Completion.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  56. BATES JE, Sanders T, Arnone A, Elmore SNC, et al
    Geographic Density of Linear Accelerators and Receipt of Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  57. KOWALCHUK RO, Breen W, Harmsen WS, Jeans E, et al
    Cost-Effectiveness of Treatment Strategies for High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  58. DEE EC, Taunk NK, Deville C Jr, Mahal BA, et al
    Trends in Receipt of Shorter Regimens of Radiation Therapy and Treatment Noncompletion Disparities Among Breast and Prostate Cancer Patients in the United States.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  59. JOOYA A, Qureshi D, Leigh J, Webber C, et al
    Barriers to Access Palliative Radiotherapy in Prostate Cancer - A Population-Based Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  60. MEEM M
    Dose-Escalated External-Beam Radiation to Prostate and Pelvic Nodes in High-Risk Prostate Cancer: Long-Term Toxicities and Outcomes at a Tertiary Center.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  61. KRUGER J, Bylund KC, Cummings MA, Frye T, et al
    Role of Pelvic Radiation in Management of Non-Metastatic Pathological Node-Positive Prostate Cancer: A Single Institution Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  62. ZAPATERO A, Castro P, Roch M, Buchser D, et al
    VMAT Focal Boost to MRI-Defined Intraprostatic Lesion in Localized Prostate Cancer: Results of a Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  63. YOON JJ, Sayan M, Wang SJ, Watts A, et al
    Effect of Hydrogel Rectal Spacer on Intrafraction Prostate Motion During Radiotherapy of Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  64. WILLEN B, Krauss DJ, Nandalur SR, Ye H, et al
    High Dose Rate Brachytherapy as Monotherapy vs. External Beam With HDR Boost in Unfavorable Intermediate Risk Localized Prostate Cancer: A Matched-Pair Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  65. WEG ES, Holt SK, Elia M, Schade G, et al
    Assessing the Risk of Pathologic Lymph Node Involvement in Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  66. TRAN PT, Berlin A, Siva S, Reynders D, et al
    Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  67. SUTERA P, Van der Eecken K, Kishan AU, Hamid A, et al
    Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  68. SMITH CP, Xiang M, Armstrong WR, Nickols NG, et al
    Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Two Prospective Ga-68-PSMA PET/CT Imaging Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  69. SHULMAN RM, Wong JK, Handorf E, Salama JK, et al
    Dosimetric Predictors of Toxicity in Patients With Early-Stage Prostate Cancer Treated With Moderately Hypofractionated IMRT or PBT: A Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  70. SHABSOVICH D, Xiang M, Katz AW, Mantz CA, et al
    Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  71. SANDOVAL ML, Latifi K, Parsee A, Andreozzi J, et al
    Defining MR-Based Parameters of Treatment Response to Immune-Modulatory Therapy for Grade Group 5 Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  72. QI X, Gao XS
    Radiotherapy of the Primary Tumor and All Metastatic Lesions in Synchronous Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  73. PAPANIKOLAOU P, Swanson GP, Stathakis S, Fakhreddine M, et al
    Estimation of Dose-Response Correlations Regarding Significant Blood Count Drops After Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  74. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  75. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Stereotactic Radiotherapy to Oligoprogressive Lesions Detected With (68)Ga-PSMA-PET/CT in Castration-Resistant Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  76. OLSON AC, Skiba JH, Gill BS, Wang H, et al
    A Prospective, Single-Arm, Phase II, Multi-Center Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  77. NIHEI K, Nakamura K, Karasawa K, Saito Y, et al
    A Japanese Multi-Institutional Phase II Study of Moderate Hypofractionated Intensity-Modulated Radiotherapy With Image-Guided Technique for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  78. NAVARRO I, Joseph L, Liu Z, Berlin A, et al
    Physician and Patient Reported Morbidity After MR-Guided Salvage Brachytherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  79. MONINGI S, Johnson HK, Peng LC, Leeman JE, et al
    Could an Academic Review of Pathology Lead to Changes in Patient Care in Men With Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  80. MISZCZYK M, Jablonska I, Krzysztofiak T, Magrowski L, et al
    Does Brachytherapy Boost Improve Biochemical Control in Intermediate and High-Risk Prostate Cancer Patients Compared to External Beam Radiotherapy Alone?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  81. MCDONALD AM, DeMora L, Lenzie A, Hoyle J, et al
    Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  82. MA W, Tao W, Hara D, Shi J, et al
    The Dual Effect of the HDAC Inhibitor Romidepsin on Androgen Receptor Signaling and DNA Damage Repair in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  83. MA TM, Roy S, Mantz CA, Fuller DB, et al
    Working Towards a New Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  84. LIN EY, Lee A, Demanes J, Kamrava M, et al
    High-Dose Rate (HDR) Brachytherapy is a Safe and Effective Treatment for Prostate Cancer Patients With Prior Transurethral Resection of the Prostate (TURP).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  85. KOONTZ BF, Hoffman KE, Oyekunle T, George DJ, et al
    Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  86. KERNS SL, Morlang A, Lee SM, Hall WA, et al
    Use of Angiotensin Converting Enzyme Inhibitors and Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  87. KAMRAN SC, Aldrighetti C, Oladeru OT, Niemierko A, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer Radiotherapy Practice Patterns: A Northeast Regional Longitudinal Survey Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  88. JENSEN GL, Hammonds K, Jhavar SG, Swanson GP, et al
    Functional Outcomes With Dose-Escalated, Conventionally Dosed, or Without Nodal Irradiation in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  89. JAWORSKI E, Fang F, Gharzai LA, McFarlane M, et al
    Utility of Long-Term Follow-Up to Determine Safety in Radiotherapy-Specific Trials for Localized Prostate Cancer: Meta-Analysis of 29 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  90. HUTTEN R, Parsons MW, Khouri A, Tward A, et al
    The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  91. HASKINS C, Siddiqui OM, Lin JY, Bentzen SM, et al
    Rectal Volume and Quality of Life in Prostate Cancer Patients Receiving Pediococcus-Based Probiotics and Radiation Therapy: A Prospective Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  92. HAAS JA, Mendez C, Katz A, Witten MR, et al
    Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  93. GOROVETS D, Tin A, Vickers AJ, Zelefsky MJ, et al
    Patient-Reported Financial Toxicity Following Definitive Radiation Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  94. GLICKSMAN R, Kishan AU, Katz AJ, Mantz CA, et al
    4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  95. LALLA VD, Elakshar S, Anidjar M, Bahoric B, et al
    Salvage External Beam Radiotherapy After HIFU Failure in Localized Prostate Cancer: A Single Institution Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  96. DHERE VR, Fischer-Valuck BW, Goyal S, Liu Y, et al
    Toxicity Outcomes After Low-Dose-Rate vs. High-Dose-Rate Brachytherapy Boost in Combination With External Beam Radiation for Intermediate and High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  97. DHERE VR, Schuster DM, Goyal S, Schreibmann E, et al
    Randomized Trial of Conventional vs Conventional Plus Fluciclovine ((18)F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  98. DELGADILLO R, Spieler B, Deana A, Ford J, et al
    Cone Beam CT Based Delta-Radiomics of Prostate Cancer Patients and Their Correlation to Quality of Life, Genitourinary and Gastrointestinal Toxicities.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  99. DEE EC, Muralidhar V, King MT, Martin NE, et al
    Association Between Treatment Modality and Probability of Second Malignancy in Localized Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  100. CORKUM MT, Morton G, Loblaw DA, Tseng CL, et al
    A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  101. CHIRILA ME, Brausi M, Chatterjee P, Gordon K, et al
    Salvage Treatments for the Local Recurrence of Prostate Cancer After Radiotherapy - Results of an International Multidisciplinary Survey.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  102. CHEUNG P, Tseng CL, Chung HR, Chu W, et al
    Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  103. CHAPMAN D, Quinn TJ, Hamstra DA
    Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  104. BRYANT CM, Henderson RH, Mendenhall WM, Nichols RC Jr, et al
    10-Year Outcomes Following Proton Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  105. BHANGOO RS, DeWees TA, Thorpe CS, Petersen M, et al
    Updated Toxicity and Quality-of-Life Outcomes From a Randomized Phase III Trial of Extreme Hypofractionated vs. Standard Fractionated Proton Therapy for Low-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  106. BERGHEN C, Joniau S, Rans K, Poels K, et al
    Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer - Preliminary Results of the Prospective, Single-Arm MEDCARE Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  107. AZGHADI S, Abdelhafez Y, Parikh M, Stephen M, et al
    Detectability Rates and Impact on Management From High-Sensitivity Total-Body (18)F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  108. ANDRUSKA N, Diaz EJ, Gay HA, Agabalogun T, et al
    Can EBRT Dose-Escalation Above 80 Gy Yield Comparable Survival Rates Relative to EBRT Plus Brachytherapy Boost in Men With Unfavorable Intermediate-Risk Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  109. AGABALOGUN T, Andruska N, Fischer-Valuck BW, Gay HA, et al
    Comparative Effectiveness of the Brachytherapy Boost and Androgen Deprivation Therapy for African-American Men with Unfavorable Intermediate-Risk Prostate Cancer Treated With External Beam Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  110. CHEBRA I
    Apoptosis and Senescence in Localized Prostate Cancer Tissues Treated With HDR-BT Boost With Radiotherapy (EBRT) and ADT.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  111. HARA D, Shi J, Tao W, Ma W, et al
    Impact of PSMA Targeted Gold Nanoparticles on Prostate Cancer Radiation Bystander Effect.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  112. RAJKUMAR AW, Wang J, Chennupati DV, Kirschner AN, et al
    Optimizing STING Activity in Prostate Cancer Pre-Clinical Models.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  113. FAIELLA A, Palermo B, Bottero M, Panetta M, et al
    Immunomonitoring During Radiotherapy of Prostate Cancer: Effect of Dose & Volume on Peripheral Immune Cells.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  114. CHEBRA I
    Effects of Androgen Deprivation Therapy (ADT) Combined With Radiotherapy (EBRT) and HDR-BT Boost on DNA Repair Markers in Prostate Carcinoma.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  115. CANTALINO JM, Singh T, Zwart A, Danner M, et al
    Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  116. GEWANTER RM, Gross J, Mazzarella K, Urban J, et al
    Does the I-PSS Accurately Assess Urinary Function in Prostate Cancer Patients? Evidence From a Study of Nursing Verification of Patient Answers.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  117. CRUICKSHANK I, Deville C Jr, Chen H, Halthore AN, et al
    Comparative In Silico Analysis of Intensity Modulated Scanning Beam Proton Therapy (IMPT) and Volumetric Modulated Arc Photon Radiotherapy (VMAT) for the Post-Operative Treatment of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  118. ZHU S, Elshaikh MA, Movsas B, Wen N, et al
    Automatic Prediction of 3D Radiation Dose Distribution in Prostate Cancer Treated with Volumetric Modulated Arc Therapy (VMAT) Using a Conditional Generative Adversarial Network (cGAN).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  119. SURESH R, Niemela J, Akram S, Valdman A, et al
    A Comparative Study Between AI-Generated, Real-Life Clinical as Well as Reference Rectal Volumes Defined in Accordance With the Swedish National STRONG Guidelines in Prostate Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  120. DUAN J, Bernard ME, Downes L, Clair WS, et al
    A Double-Blind Study to Evaluate the Feasibility of Using AI-Powered Auto-Segmentation in Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  121. BOYD GH, Efstathiou JA, Kamran SC, Zietman AL, et al
    Qualitative and Quantitative Analysis of a Deep Learning Auto Contouring Model for Radiotherapy in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  122. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
    Can Dosiomics Features Be Relevant Predictive Factors for Biochemical Recurrence After Radiotherapy in Prostate Cancer Patients?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  123. YANG F, Ghosh S, Yee D, Patel SI, et al
    Conventional vs. Hypofractionation Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24 Months Patient-Reported Quality of Life Outcomes of the Randomized Phase II CHIRP Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  124. DESS RT, Sun Y, Bolla M, Zapatero A, et al
    Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  125. KISHAN AU, Romero T, Wang X, Pisansky TM, et al
    Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  126. KWOK Y, Mirkheshti N, Naslund M, Hussain A, et al
    A Prospective Trial of Aggressive Therapy Consisting of Neoadjuvant Chemotherapy and Androgen Deprivation Followed by Prostatectomy and Adjuvant Radiation in High/Very High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  127. ZAPATERO A, Grande ADG, Maldonado X Sr, Alvarez A, et al
    10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  128. KISHAN AU, Wong JK, Merrick GS, Tran PT, et al
    The Relationship Between Androgen Deprivation Therapy Duration and External Beam Radiotherapy With or Without a Brachytherapy Boost in High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  129. MALONE S, Spratt DE, Morgan SC, Grimes S, et al
    Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Treated With Radiotherapy and ADT in a Phase III Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  130. ROY S, Morgan SC, Spratt DE, Grimes S, et al
    Association of Baseline Health-Related Quality of Life Metrics With Outcome in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  131. DE B, Pasalic D, Barocas DA, Zhao Z, et al
    Five-Year Outcomes From a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy With Low Dose-Rate Brachytherapy Boost and Prostatectomy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  132. KATZ A, Cao Y, Shen X, Usinger DS, et al
    Associations Between Knowledge of Others' Experiences and Patient Perceptions of Treatments for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  133. BOYAJIAN R, Gordon WJ, Kowtoniuk AM, Boyajian KR, et al
    Development & Impact of a Virtual PSA Monitoring Clinic for Follow-up of Prostate Cancer Patients: An Efficient Model With Unique Benefits Relevant to COVID-19.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  134. CONDE-MORENO AJ, Lopez F, Hervas A, Morillo V, et al
    Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  135. GAUDREAULT M, Chang D, Hardcastle N, Jackson P, et al
    Evaluation of PSMA-PET Biology-Guided Radiotherapy Sequential Boost to the PSMA-avid Subvolume in the Prostate Region in Low-Volume Advanced Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  136. MA TM, Xiang M, Tilki D, Karnes RJ, et al
    Prognostic Significance of the Risk of Non-localized Disease on PSMA/PET: Comparative Performance of a Novel, PSMA/PET-Derived Risk Stratification Tool for High-Risk Prostate Cancer in a Large, Multi-Institutional Cohort.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  137. HAMMER L, Jiang R, Hearn JWD, Dess RT, et al
    A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Prior to Radical Prostatectomy (RP) in Locally Advanced Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  138. NGUYEN PL, Huang HC, Davicioni E, Sandler HM, et al
    Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  139. KISHAN AU, Sun Y, Pisansky TM, Bolla M, et al
    Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  140. DAI Z, Jambor I, Taimen P, Pantelic M, et al
    Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  141. KANWAR A, Claunch C, Rana S, Merz B, et al
    Evaluation of Commercial Pelvic Autosegmentation Solutions in Anatomic Edge Cases of Patients Receiving Definitive Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  142. MOVSAS B, Rodgers J, Elshaikh MA, Martinez AA, et al
    Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  143. SPIELER B, Khodor Y, Chakrabortty S, Fischer C, et al
    Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  144. GLICKSMAN R, Liu SK, Cheung P, Vesprini D, et al
    Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: Safety and Efficacy From Four Prospective Clinical Trials.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  145. PADAYACHEE J, Sanmamed N, Lee J, Liu Z, et al
    Local Control in Tumor-Targeted Dose Escalation for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  146. YAMOAH K, Lee KM, Alba PR, Awasthi S, et al
    Defining Racial Disparities Across the Prostate Cancer Disease Continuum in an Equal Access-to-Care Setting Within the Nation's Largest Healthcare Network.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  147. GLICKSMAN R, Loblaw DA, Morton G, Szumacher E, et al
    Elective Pelvic Nodal Irradiation With A Simultaneous Hypofractionated Integrated Prostate Boost for Localized High Risk Prostate Cancer: Long Term Results From a Prospective Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  148. SALERNO KE, Turkbey B, Lindenberg L, Mena E, et al
    Detection of Failure Patterns Using Advanced Imaging in Patients With Biochemical Recurrence Following Low Dose Rate Brachytherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  149. KRAUSS DJ, Karrison TG, Martinez AA, Morton G, et al
    Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


    October 2021
  150. MUSUNURU HB, Cheung P, Vesprini D, Liu SK, et al
    Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost.
    Int J Radiat Oncol Biol Phys. 2021 Oct 9. pii: S0360-3016(21)02899.
    PubMed     Abstract available


    September 2021
  151. JONES CU, Pugh SL, Sandler HM, Chetner MP, et al
    Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.
    Int J Radiat Oncol Biol Phys. 2021 Sep 1. pii: S0360-3016(21)02724.
    PubMed     Abstract available


  152. NAGAR H, Spratt DE
    Prostate SBRT Dose Escalation (9 Gyx5, 13.3 Gyx3, 24 Gyx1): Are We Making Progress?
    Int J Radiat Oncol Biol Phys. 2021;111:110-112.
    PubMed    


    August 2021
  153. NUIJENS AC, Oei AL, van Oorschot B, Visser J, et al
    Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02708.
    PubMed     Abstract available


  154. MURAKAMI Y, Soyano T, Kozuka T, Ushijima M, et al
    Dose-based radiomic analysis (dosiomics) for intensity-modulated radiotherapy in patients with prostate cancer: Correlation between planned dose distribution and biochemical failure.
    Int J Radiat Oncol Biol Phys. 2021 Aug 5. pii: S0360-3016(21)02627.
    PubMed     Abstract available


  155. FERREIRA MR, Sands CJ, Li JV, Andreyev JN, et al
    Impact of pelvic radiotherapy for prostate cancer on global metabolic profiles and microbiota-driven gastrointestinal late side-effects: a longitudinal observational study.
    Int J Radiat Oncol Biol Phys. 2021 Aug 2. pii: S0360-3016(21)02626.
    PubMed     Abstract available


  156. LEITE ETT, Ramos CCA, Moraes FY
    In Reply to Fiorino et al.
    Int J Radiat Oncol Biol Phys. 2021;110:1549-1550.
    PubMed    


  157. ARAI TJ, Yang DM, Campbell JW 3rd, Chiu T, et al
    Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?
    Int J Radiat Oncol Biol Phys. 2021;110:1519-1529.
    PubMed     Abstract available


  158. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
    Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
    Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
    PubMed     Abstract available


    July 2021
  159. PARZEN JS, Hamstra DA
    Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience.
    Int J Radiat Oncol Biol Phys. 2021;110:1129-1131.
    PubMed    


  160. CHOUDHURY A, Henry Md Frcr A, Mitin Md PhD T, Chen Md Mph R, et al
    Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team.
    Int J Radiat Oncol Biol Phys. 2021;110:1114-1121.
    PubMed    


  161. EFSTATHIOU JA, Kamran SC, Spratt DE
    Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming.
    Int J Radiat Oncol Biol Phys. 2021;110:1098-1100.
    PubMed    


  162. PARKER C
    Timing of Postoperative Radiation Therapy After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2021;110:1132-1134.
    PubMed    


  163. YANG Y, Vargas CE, Bhangoo RS, Wong WW, et al
    Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT).
    Int J Radiat Oncol Biol Phys. 2021;110:1189-1199.
    PubMed     Abstract available


  164. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
    Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
    PubMed     Abstract available


  165. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
    First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
    PubMed     Abstract available


  166. KISHAN AU, Collins SP
    Quality of Life After Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;110:727-730.
    PubMed    


  167. MOHAMAD O, Feng F
    Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
    Int J Radiat Oncol Biol Phys. 2021;110:634-635.
    PubMed    


  168. BELKACEMI Y, Coraggio G, Loganadane G
    Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
    Int J Radiat Oncol Biol Phys. 2021;110:631-632.
    PubMed    


  169. RANS K, De Meerleer G, Joniau S, Baten A, et al
    In Regard to Zelefsky et al.
    Int J Radiat Oncol Biol Phys. 2021;110:910-911.
    PubMed    


  170. WALSHAW RC, Hoskin PJ, Choudhury A
    Can Hypofractionation and Immune Modulation Coexist?
    Int J Radiat Oncol Biol Phys. 2021;110:742-744.
    PubMed    


  171. WALLIS CJD, Klotz L, Satkunasivam R, Klaassen Z, et al
    Not So "Active" Surveillance.
    Int J Radiat Oncol Biol Phys. 2021;110:716-717.
    PubMed    


  172. SHORTALL J, Palma G, Mistry H, Vasquez Osorio E, et al
    Flogging a Dead Salmon? Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2021;110:696-699.
    PubMed    


  173. CHEN RC
    A Trans-Atlantic Voyage of Extended ADT With Local Radiation.
    Int J Radiat Oncol Biol Phys. 2021;110:633.
    PubMed    


  174. VAN DAMS R, Jiang NY, Fuller DB, Loblaw A, et al
    Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
    Int J Radiat Oncol Biol Phys. 2021;110:731-737.
    PubMed     Abstract available


  175. HSU IC, Rodgers JP, Shinohara K, Purdy J, et al
    Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
    Int J Radiat Oncol Biol Phys. 2021;110:700-707.
    PubMed     Abstract available


    June 2021
  176. BRAND DH, Bruningk SC, Wilkins A, Fernandez K, et al
    Estimates of Alpha/Beta (alpha/beta) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:596-608.
    PubMed     Abstract available


    May 2021
  177. NITHIYANANTHAN K, Creighton N, Currow D, Martin JM, et al
    Population-Level Uptake of Moderately Hypofractionated Definitive Radiotherapy in the Treatment of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 8. pii: S0360-3016(21)00460.
    PubMed     Abstract available


  178. HARA D, Tao W, Totiger T, Pourmand A, et al
    Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA).
    Int J Radiat Oncol Biol Phys. 2021 May 5. pii: S0360-3016(21)00459.
    PubMed     Abstract available


  179. WANG K, Mavroidis P, Royce TJ, Falchook AD, et al
    Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
    Int J Radiat Oncol Biol Phys. 2021;110:237-248.
    PubMed     Abstract available


    April 2021
  180. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
    OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
    Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
    PubMed     Abstract available


  181. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
    FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
    Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.
    PubMed    


  182. YAMAZAKI H, Suzuki G, Aibe N, Yoshida K, et al
    Posterior Margins in Prostate Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1657-1658.
    PubMed    


  183. MITCHELL D, Jain S
    Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?
    Int J Radiat Oncol Biol Phys. 2021;109:1230-1231.
    PubMed    


  184. LEITE ETT, Ramos CCA, Ribeiro VAB, Salvajoli BP, et al
    Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:1263-1270.
    PubMed     Abstract available


  185. FU SY, Chen FH, Wang CC, Yu CF, et al
    Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
    Int J Radiat Oncol Biol Phys. 2021;109:1547-1558.
    PubMed     Abstract available


  186. ROBIN S, Jolicoeur M, Palumbo S, Zilli T, et al
    Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1243-1253.
    PubMed     Abstract available


    March 2021
  187. FOLKERT MR, Zelefsky MJ, Hannan R, Desai NB, et al
    A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 19. pii: S0360-3016(21)00285.
    PubMed     Abstract available


  188. MAGLI A, Farneti A, Faiella A, Ferriero M, et al
    Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 18. pii: S0360-3016(21)00287.
    PubMed     Abstract available


  189. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
    Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2021;109:718-725.
    PubMed     Abstract available


  190. SHAHI J, Poon I, Ung YC, Tsao M, et al
    Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:764-774.
    PubMed     Abstract available


    February 2021
  191. BUBLEY GJ, Kaplan I, Bhatt R, Taplin ME, et al
    Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.
    Int J Radiat Oncol Biol Phys. 2021 Feb 23. pii: S0360-3016(21)00205.
    PubMed     Abstract available


  192. KUBES J, Haas A, Vondracek V, Andrlik M, et al
    Ultra-hypofractionated proton radiotherapy in the treatment of low- and intermediate-risk prostate cancer - 5-years outcomes.
    Int J Radiat Oncol Biol Phys. 2021 Feb 12. pii: S0360-3016(21)00189.
    PubMed     Abstract available


  193. VAPIWALA N, Wong JK, Handorf E, Paly J, et al
    A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00117.
    PubMed     Abstract available


  194. SUD S, Gerringer BC, Wacaser B, Tan X, et al
    Under-ascertainment of clinically-meaningful symptoms during prostate cancer radiation therapy - does this vary by patient characteristics?
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00108.
    PubMed     Abstract available


    January 2021
  195. ROY S, Grimes S, Morgan SC, Eapen L, et al
    Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jan 29. pii: S0360-3016(21)00092.
    PubMed     Abstract available


  196. CHEN RC, Prime SG, Basak R, Moon DH, et al
    Receipt of guideline-recommended surveillance in a population-based cohort of active surveillance prostate cancer patients.
    Int J Radiat Oncol Biol Phys. 2021 Jan 13. pii: S0360-3016(21)00034.
    PubMed     Abstract available


    December 2020
  197. GARIN O, Suarez JF, Guedea F, Pont A, et al
    Comparative Effectiveness Research in Localized Prostate Cancer: a 10-Year follow-up Cohort Study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 31. pii: S0360-3016(20)34728.
    PubMed     Abstract available


  198. CHEN WC, Li Y, Lazar A, Altan A, et al
    Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.
    Int J Radiat Oncol Biol Phys. 2020 Dec 29. pii: S0360-3016(20)34730.
    PubMed     Abstract available


  199. TANG C, Lei X, Smith GL, Pan HY, et al
    Influence of Geography on Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2020 Dec 11. pii: S0360-3016(20)34595.
    PubMed     Abstract available


  200. PARRY MG, Nossiter J, Sujenthiran A, Cowling TE, et al
    Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 3. pii: S0360-3016(20)34545.
    PubMed     Abstract available


  201. DEE EC, Muralidhar V, Arega MA, Kishan AU, et al
    Factors influencing non-completion of radiotherapy among men with localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Dec 1. pii: S0360-3016(20)34604.
    PubMed     Abstract available


  202. JANI A, Schreibmann E, Goyal S, Raghuveer H, et al
    Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine ((18)F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:1397.
    PubMed    


  203. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
    Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
    PubMed     Abstract available


    November 2020
  204. KOONTZ BF, Hoffman KE, Halabi S, Healy P, et al
    Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 28. pii: S0360-3016(20)34599.
    PubMed     Abstract available


  205. WAGES NA, Sanders JC, Smith A, Wood S, et al
    Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial.
    Int J Radiat Oncol Biol Phys. 2020 Nov 20. pii: S0360-3016(20)34497.
    PubMed     Abstract available


  206. SPENCER KL, Tree AC
    Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:927-929.
    PubMed    


  207. DESAI NB, Garant A, Hannan R, Folkert MR, et al
    Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation.
    Int J Radiat Oncol Biol Phys. 2020;108:914-916.
    PubMed    


  208. BOHMER D, Hocht S, Wiegel T
    Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
    Int J Radiat Oncol Biol Phys. 2020;108:903-904.
    PubMed    


  209. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
    A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
    PubMed     Abstract available


  210. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
    Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
    Int J Radiat Oncol Biol Phys. 2020;108:936-940.
    PubMed     Abstract available


  211. TAKAGI M, Demizu Y, Fujii O, D KT, et al
    Proton Therapy for Localized Prostate Cancer: Long-term Results in 2,021 Patients.
    Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34493.
    PubMed     Abstract available


  212. GOGINENI E, Rana Z, Soberman D, Sidiqi B, et al
    Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 7. pii: S0360-3016(20)34489.
    PubMed     Abstract available


  213. BERK L, Lopez Alfonso JC
    Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer In Regard to Vogelius et al.
    Int J Radiat Oncol Biol Phys. 2020;108:834.
    PubMed    


  214. THOMPSON AB, Hamstra DA
    Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:644-648.
    PubMed    


  215. VOGELIUS IR, Bentzen SM
    In Reply to Berk and Alfonso.
    Int J Radiat Oncol Biol Phys. 2020;108:834-835.
    PubMed    


  216. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed     Abstract available


  217. MAO X, Pineau J, Keyes R, Enger SA, et al
    RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
    Int J Radiat Oncol Biol Phys. 2020;108:802-812.
    PubMed     Abstract available


    October 2020
  218. HOFFMAN KE
    Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:340.
    PubMed    


  219. LEEMAN JE, Nguyen PL
    Less Is More During COVID 19.
    Int J Radiat Oncol Biol Phys. 2020;108:339.
    PubMed    


  220. SPRATT DE
    Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion.
    Int J Radiat Oncol Biol Phys. 2020;108:338-339.
    PubMed    


  221. MOHAMAD O, Roach M 3rd
    Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:337.
    PubMed    


  222. LING DC, Vargo JA, Beriwal S
    Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
    Int J Radiat Oncol Biol Phys. 2020;108:390-393.
    PubMed    


  223. ZAORSKY NG
    Prostate and Pelvis on Pause Pending a Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:341-342.
    PubMed    


  224. KOONTZ BF
    Through COVID-Colored Glasses: New Perspectives on Same Data.
    Int J Radiat Oncol Biol Phys. 2020;108:338.
    PubMed    


    September 2020
  225. SANDERS JW, Venkatesan AM, Levitt CA, Bathala T, et al
    Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study.
    Int J Radiat Oncol Biol Phys. 2020 Sep 24. pii: S0360-3016(20)34342.
    PubMed     Abstract available


  226. SPRATT DE, Tward JD
    Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Sep 11. pii: S0360-3016(20)31252.
    PubMed    


  227. ROYCE TJ, Mavroidis P, Wang K, Falchook AD, et al
    Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Sep 5. pii: S0360-3016(20)34102.
    PubMed     Abstract available



  228. Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Rad
    Int J Radiat Oncol Biol Phys. 2020;108:328.
    PubMed    


    August 2020
  229. HALL WA, Paulson E, Davis BJ, Spratt DE, et al
    NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34124.
    PubMed     Abstract available


  230. DEEK MP, Taparra K, Dao D, Chan L, et al
    Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 13. pii: S0360-3016(20)34120.
    PubMed     Abstract available


  231. PALY J, Horwitz EM
    Less Is More: Treatment of Locally Advanced Small Cell Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;107:865-866.
    PubMed    


  232. DALWADI SM, Zhu A
    Big Small Cell Dilemma.
    Int J Radiat Oncol Biol Phys. 2020;107:863-864.
    PubMed    


  233. ABU-GHEIDA I, Bathala TK, Maldonado JA, Khan M, et al
    Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers.
    Int J Radiat Oncol Biol Phys. 2020;107:982-985.
    PubMed     Abstract available


    July 2020
  234. PARRY MG, Nossiter J, Cowling TE, Sujenthiran A, et al
    Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.
    Int J Radiat Oncol Biol Phys. 2020 Jul 24. pii: S0360-3016(20)31450.
    PubMed     Abstract available


  235. MITIN T, Choudhury A
    Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
    Int J Radiat Oncol Biol Phys. 2020;107:609-612.
    PubMed    


  236. WANG Y, Chen H
    In Reply to Ghadjar et al.
    Int J Radiat Oncol Biol Phys. 2020;107:856.
    PubMed    


  237. MYLONA E, Ebert M, Kennedy A, Joseph D, et al
    Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer Radiotherapy: validation of voxel-based models in an independent population.
    Int J Radiat Oncol Biol Phys. 2020 Jul 13. pii: S0360-3016(20)31417.
    PubMed     Abstract available


  238. BERGAMIN S, Eade T, Kneebone A, Booth J, et al
    Interim results of a prospective PSMA-directed focal stereotactic re-irradiation trial for locally recurrent prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 10. pii: S0360-3016(20)31412.
    PubMed     Abstract available


  239. SANDERS JW, Lewis GD, Thames HD, Kudchadker RJ, et al
    Machine segmentation of pelvic anatomy in MRI-assisted radiosurgery (MARS) for prostate cancer brachytherapy.
    Int J Radiat Oncol Biol Phys. 2020 Jul 4. pii: S0360-3016(20)31396.
    PubMed     Abstract available


  240. VAN SCHIE MA, Janssen TM, Eekhout D, Walraven I, et al
    Knowledge-based assessment of focal dose escalation treatment plans in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 3. pii: S0360-3016(20)31392.
    PubMed     Abstract available


    June 2020
  241. ROY S, Grimes S, Eapen L, Spratt DE, et al
    Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
    PubMed     Abstract available


  242. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
    Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
    PubMed     Abstract available


  243. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
    Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
    PubMed     Abstract available


  244. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
    Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
    PubMed     Abstract available


  245. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
    Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
    PubMed    



  246. Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Res
    Int J Radiat Oncol Biol Phys. 2020;107:390.
    PubMed    


  247. YUCE SARI S, Elmali A, Arslan S, Ozyigit G, et al
    In Regard to Aksnessaetheret al.
    Int J Radiat Oncol Biol Phys. 2020;107:387-388.
    PubMed    


  248. CHIN S, Fatimilehin A, Walshaw R, Argarwal A, et al
    Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
    Int J Radiat Oncol Biol Phys. 2020;107:288-296.
    PubMed     Abstract available


    May 2020
  249. GHADJAR P, Zwahlen DR, Hayoz S, Aebersold DM, et al
    In Regard to Qi et al.
    Int J Radiat Oncol Biol Phys. 2020;107:224-225.
    PubMed    


  250. GUNTHER JR
    Involved-Site Radiation Therapy if Minimal Toxicity.
    Int J Radiat Oncol Biol Phys. 2020;107:20-21.
    PubMed    


  251. ALAYED Y, Davidson M, Liu S, Chu W, et al
    Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
    Int J Radiat Oncol Biol Phys. 2020;107:136-142.
    PubMed     Abstract available


    April 2020
  252. QIN H, Zhang V, Bok RA, Santos RD, et al
    Simultaneous metabolic and perfusion imaging using hyperpolarized (13)C MRI can evaluate early and dose-dependent responses to radiotherapy in a prostate cancer mouse model.
    Int J Radiat Oncol Biol Phys. 2020 Apr 24. pii: S0360-3016(20)31042.
    PubMed     Abstract available


  253. MCCLELLAND S 3RD, Petereit DG
    The Advanced Alternative Payment Model: Catalyst for Prostate Brachytherapy Adoption?
    Int J Radiat Oncol Biol Phys. 2020;106:1104-1105.
    PubMed    


  254. WILKINS A, Naismith O, Brand D, Fernandez K, et al
    Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
    Int J Radiat Oncol Biol Phys. 2020;106:928-938.
    PubMed     Abstract available


    March 2020
  255. KEALL P, Nguyen DT, O'Brien R, Hewson E, et al
    Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial.
    Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30937.
    PubMed     Abstract available


  256. ACHARD V, Zilli T
    In Regard to Qi et al.
    Int J Radiat Oncol Biol Phys. 2020;106:887-888.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: